NCT07424235Completed
Evaluating the Relationship Between Function and Structure Using Data From a GA Natural History Cohort
Anatomical and Retinal CHanges Evaluated in Real-life GeographY Atrophy
Source: ClinicalTrials.gov · Last updated 11 May 2026
Brief summary (registry, in English)
Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration that leads to progressive and irreversible vision loss. The course of visual decline varies widely among patients, and it is not always clear which anatomical features of the retina are associated with faster loss of vision. This retrospective observational study aims to describe the natural history of vision loss in patients with geographic atrophy who have characteristics similar to those enrolled in recent clinical trials. The study will analyze previously collected clinical and imaging data from patients followed during routine clinical care at a single center. The main goal of the study is to evaluate the relationship between changes in visual function and retinal anatomical features, such as the size and location of atrophic lesions and retinal layer integrity, using fundus autofluorescence and optical coherence tomography images. No treatments or study procedures are performed as part of this research. All data used in the study were collected during standard clinical practice and analyzed retrospectively.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 60 (actual)
- First submitted
- 13 Feb 2026
- Start date
- Jan 2015
- Primary completion date
- Dec 2024
- Lead sponsor
- IRCCS Ospedale San Raffaele
- Diseases
- Macular degeneration
- NCT number
- NCT07424235
What you commit to
- Study type: Observational
- Participants enrolled: 60
- From Jan 2015 to the primary completion date, Dec 2024
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior intravitreal therapy or systemic treatments specifically targeting age-related macular degeneration.
Other illness
- Coexisting ocular diseases that could independently affect visual acuity or retinal structure.
Age
- Evidence or history of neovascular (wet) age-related macular degeneration in the study eye.
Other
- Geographic atrophy lesions contiguous with peripapillary atrophy.
- Incomplete or poor-quality clinical or imaging data precluding reliable assessment of study outcomes.
Who the study is looking for
- Male or female patients aged 50 years or older at baseline.
- Diagnosis of geographic atrophy secondary to dry age-related macular degeneration in the study eye.
- Well-demarcated geographic atrophy lesions confirmed by fundus autofluorescence imaging, with a total lesion area between 2.5 mm² and 17.5 mm².
- Presence of hyperautofluorescence in the junctional zone of the geographic atrophy lesion.
- Best-corrected visual acuity between 45 and 83 ETDRS letters at baseline.
- Availability of longitudinal clinical and imaging data with at least 6 months of follow-up.
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.